Back to search results

Hospital-at-Home for People Receiving Tarlatamab for Small Cell Lung Cancer

This study is looking at whether a Hospital-at-Home (HaH) program is an effective way to monitor your health after you receive tarlatamab for extensive stage small cell lung cancer. Tarlatamab is a standard treatment for this type of cancer. The study will involve a SeniorCare community paramedic visiting your home after you are discharged from the hospital. Researchers want to see if this home-based monitoring can reduce the number of days you spend in the hospital. You may be eligible if you are 18 or older, have extensive stage small cell lung cancer, and are receiving tarlatamab. The study aims to enroll 70 participants, but its current status is unclear.

Study design
This is an interventional study planning to enroll 70 participants. It is not specified if it is randomized or blinded.
What's involved
After discharge, a SeniorCare community paramedic will provide a home visit to your home or residence.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, number of inpatient hospital days, is measured at 14 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06957314

A Study of Hospital-at-Home for People Receiving Tarlatamab

Recruiting
NAAges 18+InterventionalHealth services
Memorial Sloan Kettering Cancer Center
~70 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:Hospital-at-Home/HAH

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of inpatient hospital days
Measured over 14 days

Conditions

Small-cell Lung Cancer
Small Cell Lung Carcinoma

Explore related trials

Lung Small Cell Carcinoma

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Robert Daly, MD, MBA · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Robert Daly, MD, MBA
[email protected]
646-608-3789
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of extensive stage small cell lung carcinoma (ES-SCLC)
Treatment plan of commercially available tarlatamab monotherapy as standard of care
Patients must be 18 years of age or older
Eastern Cooperative Oncology Group (ECOG) performance status \<2
Patients must have adequate organ and bone marrow function, defined by the following laboratory results obtained within 28 days prior to the first study treatment:
ANC ≥ 1000 cells/μL (without granulocyte colony stimulating factor support within 4 weeks prior to Cycle 1, Day 1)
Platelet count ≥50,000/μL (without transfusion within 4 weeks prior to Cycle 1, Day 1)
Hemoglobin ≥8.0 g/dL (without transfusion within 4 weeks prior to Cycle 1, Day 1)
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 3 X upper limit of normal (ULN). Serum bilirubin ≤ 1.5 x ULN. Patients with known Gilbert disease who have serum bilirubin level ≤ 2 x ULN may be enrolled.
Estimated Glomerular Filtration Rate (eGFR) ≥ 30mL/min using the CKD-EPI formula.
The patient is willing to give and sign informed consent
Appropriate homebound setting as defined by one of the following:
Lodging at MSK Residence or hotel
5 New York City boroughs, lower Westchester County (northern boundary Cross County Parkway) and Nassau County (eastern boundary Wantagh State Parkway). This is based on the community paramedic (SeniorCare) 60-minute response time catchment area. If there is any uncertainty about patient residence eligibility, the Principal Investigator will decide after discussion with SeniorCare.
Patients must be accompanied by a caregiver for the period of time the patient is enrolled in the HaH intervention. For cases where there is uncertainty, the Principal Investigator will make the final determination.
Primary caregiver as identified by patient enrolled on study
Treating physician for patient(s) enrolled on study; managing treatment plan of commercially available tarlatamab as standard of care

Exclusion

Patients with a documented active infection prior to starting tarlatamab. This includes grade 3 or higher viral, bacterial, or fungal infection.
Patients with baseline dementia or cognitive barriers
Uncontrolled arrhythmias
Caregiver deemed inappropriate by treating physician

What this trial measures

  • Number of inpatient hospital days14 days

    Evaluate whether HaH in combination with an enhanced oncology specific telemedicine platform is efficient by quantifying inpatient hospital days during the two 7-day periods (14 days total) after the tarlatamab infusions scheduled for C1D1 and C1D8